Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study
Author:
Funder
AstraZeneca
Janssen Pharmaceuticals Inc
Amgen Inc
Astellas Pharma Inc
AstraZeneca Australia
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference39 articles.
1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004
2. Relation between pain and skeletal metastasis in patients with prostate or breast cancer;Levren;Clin Physiol Funct Imag,2011
3. The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres;Saad;Can Urol Assoc J,2018
4. Incidence of skeletal-related events in men with castration-resistant prostate cancer;Kawai;J Clin Oncol,2018
5. Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: the impact of alternative measures of radiation to the bone;Onukwugha;PloS One,2017
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Construction of a predictive model for bone metastasis from first primary lung adenocarcinoma within 3 cm based on machine learning algorithm: a retrospective study;PeerJ;2024-03-14
2. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System;JCO Oncology Practice;2024-01
3. A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases;European Journal of Cancer;2023-03
4. Vertical integration of oncologists and cancer outcomes and costs in metastatic castration-resistant prostate cancer;JNCI: Journal of the National Cancer Institute;2022-12-30
5. Osteoprotektion beim ossär metastasierten kastrationsresistenten Prostatakarzinom (mCRPC): Aktuelle Daten aus Deutschland, vorgelegt von d-uo;Aktuelle Urologie;2022-11-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3